Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions.

Molecular therapy. Oncology·2026

Same author

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Nature medicine·2026

Same author

[Meningeal syndrome in an immunocompromised patient].

Annales de pathologie·2026

Same author

[Cerebrospinal fluid in the context of headaches with decreased visual acuity].

Annales de pathologie·2026

Same author

Annales de pathologie·2026

Same author

Exploratory assessment of phosphorylated TDP-43 immunoreactivity in minor salivary glands of patients with ALS.

Acta neuropathologica communications·2026

Same journal

[Mucinous carcinomas across organs: Definitions, profiles, diagnostic pitfalls and practical implications for pathologists].

Annales de pathologie·2026

Same journal

Annales de pathologie·2026

Same journal

[Case no. 2. Pseudotumoral pulmonary IgG4 disease].

Annales de pathologie·2026

Same journal

[Diffuse large B-cell lymphoma-NOS , high-grade B-cell lymphomas and Burkitt lymphoma: Updates].

Annales de pathologie·2026

Same journal

[Ironing out the diagnosis].

Annales de pathologie·2026

Same journal

[Ecological transformation and quality of surgical pathological analysis: Not such an insoluble equation].

Annales de pathologie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 8, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

[Immunotherapy in brain tumors].

Emilie De Carli¹, Matthieu Delion², Audrey Rousseau³

¹Unité hémato-onco-immunologie pédiatrique, fédération de pédiatrie, CHU d'Angers, 4, rue Larrey, 49000 Angers, France.

Annales De Pathologie

|January 24, 2017

Summary

This summary is machine-generated.

Diffuse gliomas, including glioblastoma, are aggressive brain tumors requiring new treatments. Immunotherapy offers a promising avenue, with vaccination and T cell transfer showing potential, especially in adults.

Keywords:

Adoptive T cell transfer Blocage des points de contrôle immunitaires Brain tumor Diffuse glioma Glioblastoma Glioblastome Gliome diffus Immune checkpoint blockade Immunotherapy Immunothérapie Transfert adoptif de lymphocytes T Tumeur cérébrale Tumor vaccine Vaccin tumoral

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Mar 8, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Neuro-oncology
Immunology

Background:

Diffuse gliomas are the most common primary central nervous system tumors in adults and children.
Glioblastoma, the most malignant form, has a poor prognosis with a median survival of 15 months.
Conventional treatments for diffuse gliomas are often insufficient, necessitating novel therapeutic strategies.

Purpose of the Study:

To review the current landscape and future directions of immunotherapy for diffuse gliomas.
To highlight promising immunotherapy modalities and their potential in clinical trials.

Main Methods:

Review of clinical trials and scientific literature on diffuse glioma immunotherapy.
Analysis of established and emerging immunotherapeutic approaches.

Main Results:

Immunotherapy, including vaccination, immune checkpoint blockade, and adoptive T cell transfer, shows promise in glioma treatment.
These approaches have demonstrated encouraging results, particularly in adult patients.
The central nervous system's immune privilege is being overcome by novel immunotherapeutic strategies.

Conclusions:

Immunotherapy represents a novel and promising approach for managing diffuse glioma patients.
Combinatorial strategies involving conventional treatments and immunotherapy are likely the future of glioma treatment.
Further research is needed to optimize treatment schedules for combined therapies.